Molecular Transmission Network and Pretreatment Drug Resistance of Newly Diagnosed HIV-1 Infections in Taizhou, a Coastal City in Eastern China, from 2021–2023
Pathogens · 2025
DOI: 10.3390/pathogens14101030 ↗At a glance
Journal article in Pathogens, 2025. Written by Junxiao Lin and 9 co-authors. Institution: Taizhou Municipal Center for Disease Control and Prevention, Taizhou Municipal Institute of Health Supervision, No 4123, Zhongxin Avenue, Taizhou 318…. Major MEDLINE topics: HIV-1, HIV Infections, Drug Resistance, Viral. Cited 4 times so far (Crossref); 34 references. The full text is freely available (open access, CC BY 4.0). Funded by: Special Support Program for High Level Talents in Taizhou City, Projects of the Special Support Program for High-Level Talents in Taizhou City.
Abstract (original language)
Objective
This study conducted a comprehensive analysis of molecular transmission networks and pretreatment drug resistance (PDR) in newly diagnosed HIV-1 infections in Taizhou, China.
Methods
From 2021 to 2023, we collected 1126 plasma samples from newly diagnosed HIV patients in Taizhou. The HIV pol gene was amplified, and the obtained sequence was used to construct a maximum likelihood (ML) phylogenetic tree and molecular transmission network. PDR-related mutations were analyzed based on the Stanford University HIV Resistance Database. We conducted genotyping analysis and analysis of factors related to the larger clusters (≥10).
Results
We successfully amplified and sequenced the pol region from 937 (83.2%, 937/1126) treatment-naïve HIV-1 patients, each with comprehensive epidemiological documentation. Phylogenetic characterization revealed significant subtype heterogeneity, with CRF07_BC (42.1%, 395/937), CRF01_AE (27.6%, 259/937) and CRF08_BC (22.1%, 209/937) being the most prevalent. Notably, 11.4% of the sequenced population (107/937) presented detectable PDR mutations. Univariate analysis revealed that larger clusters (≥10) are more inclined to be aged ≥60, divorced or widowed, have high or technical secondary school education, and have sexual contact with homosexuality. Multivariate analysis revealed that age ≥60 years and not having a PDR mutation (p < 0.05) were factors associated with larger clusters (≥10).
Conclusions
Molecular transmission networks suggest that CRF08_BC is spreading rapidly among the older male population. Consequently, targeted interventions aimed at this population are crucial for halting the ongoing rapid dissemination of this subtype.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Taizhou Municipal Center for Disease Control and Prevention, Taizhou Municipal Institute of Health Supervision, No 4123, Zhongxin Avenue, Taizhou 318000, China.
- Department of HIV/AIDS Control and Prevention, Zhejiang Provincial Center for Disease Control and Prevention, No. 3399, Binsheng Road, Hangzhou 310051, China.
ORCID profiles: Qiguo Meng, Jiafeng Zhang
Funding
- Special Support Program for High Level Talents in Taizhou City
- Projects of the Special Support Program for High-Level Talents in Taizhou City
Cite
APA
Lin, J., Lin, H., Li, G., Wang, S., Wang, T., Meng, Q., Hua, T., Xie, Y., Zhang, J., & Shen, W. (2025). Molecular Transmission Network and Pretreatment Drug Resistance of Newly Diagnosed HIV-1 Infections in Taizhou, a Coastal City in Eastern China, from 2021–2023. Pathogens. https://doi.org/10.3390/pathogens14101030
Vancouver
Lin J, Lin H, Li G, Wang S, Wang T, Meng Q, et al. Molecular Transmission Network and Pretreatment Drug Resistance of Newly Diagnosed HIV-1 Infections in Taizhou, a Coastal City in Eastern China, from 2021–2023. Pathogens. 2025. doi:10.3390/pathogens14101030
BibTeX
@article{Lin2025,
author = {Lin, Junxiao and Lin, Haijiang and Li, Guixia and Wang, Shanling and Wang, Tingting and Meng, Qiguo and Hua, Tingting and Xie, Yali and Zhang, Jiafeng and Shen, Weiwei},
title = {Molecular Transmission Network and Pretreatment Drug Resistance of Newly Diagnosed HIV-1 Infections in Taizhou, a Coastal City in Eastern China, from 2021–2023},
journal = {Pathogens},
year = {2025},
doi = {10.3390/pathogens14101030}
}
EUVIMED